Evidence map›Paper›PMID 40064798›Full record

ArticleAnnals of surgical oncology2025

Identification of Predictive Factors for the Development of In-Transit Metastasis in Patients with Melanoma.

Anne Huibers, Stanley P Leong, Mohammed Kashani-Sabet, Richard L White, John Vetto, Schlomo Schneebaum, Cristina O'Donoghue, Harrison Howard, Eli Avisar, Jukes P Namm and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Anne HuibersDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. anne.huibers@vgregion.se.
Stanley P LeongCenter for Melanoma Research and Treatment, California Pacific Medical Center and Research Institute, San Francisco, CA, USA.
Mohammed Kashani-SabetCenter for Melanoma Research and Treatment, California Pacific Medical Center and Research Institute, San Francisco, CA, USA.
Richard L WhiteDepartment of Surgery, Atrium Health Levine Cancer, Charlotte, NC, USA.
John VettoDepartment of Surgery and Division of Surgical Oncology, Oregon Health and Science University, Portland, OR, USA.
Schlomo SchneebaumDepartment of Surgery, Tel Aviv University, Tel Aviv, Israel.
Cristina O'DonoghueDepartment of Surgery, Rush University Medical Center, Chicago, IL, USA.
Harrison HowardDepartment of Surgery, University of South Alabama, Mobile, AL, USA.
Eli AvisarDepartment of Surgical Oncology, University of Miami School of Medicine, Miami, FL, USA.
Jukes P NammDepartment of Surgery, Loma Linda University, Loma Linda, CA, USA.
Heidi KosiorekDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.
Mark FariesDepartment of Surgery, Cedars-Sinai Medical Center, Angeles Clinic and Research Institute, Los Angeles, CA, USA.
Giorgos KarakousisDivision of Endocrine and Oncologic Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Jonathan S ZagerDepartments of Cutaneous Oncology and Sarcoma, Moffit Cancer Center, Tampa, FL, USA.
Roger Olofsson BaggeDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
on behalf of the Sentinel Lymph Node Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn patients with melanoma, in-transit metastasis (ITM) can develop. This study aimed to identify the risk for a first recurrence of ITM and associated predictive clinical factors in a large international cohort of patients with melanoma.

methodsPatients with primary cutaneous melanoma who underwent wide local excision (WLE) and sentinel lymph node biopsy (SLNB) were identified from the Sentinel Lymph Node Working Group (SLNWG) database between January 1993 and February 2023. Predictive factors for first recurrence of ITM were analyzed.

resultsThe study enrolled 7860 patients, and the median follow-up time was 47.1 months (interquartile range [IQR], 19.0-95.0 months). The risk for the development of ITM as a first recurrence was 4.12% (95% confidence interval [CI], 3.63-4.66%) at 5 years. The median time to first ITM recurrence was 15 months (IQR, 7.0-30.0 months). Significant clinicopathologic factors independently associated with an increased risk of ITM in multivariable analysis were increasing Breslow thickness (hazard ratio [HR], 1.37; 95% CI, 1.30-1.43; p < 0.0001), lower-extremity versus trunk melanoma (HR, 2.49; 95% CI, 1.86-3.32; p < 0.0001), increasing age (HR, 1.03; 95% CI, 1.02-1.04; p < 0.0001), number of positive sentinel lymph nodes (SLNs: 1 vs. 0 [HR, 2.24; 95% CI, 1.66-3.01; p < 0.0001] and 2 vs. 0 [HR, 2.37; 95% CI, 1.45-3.88; p = 0.0006]), and presence of vascular invasion (HR, 1.79; 95% CI, 1.21-2.64; p = 0.0035).

conclusionThe independent risk factors for the development of ITM identified in a large international cohort of melanoma patients were Breslow thickness, lower-extremity melanoma, older age, number of positive SLNs, and presence of vascular invasion.

Indexed as

MelanomaNeoplasm Recurrence, LocalSentinel Lymph NodeSkin NeoplasmsAdultAgedFemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMiddle AgedPrognosisRetrospective StudiesRisk FactorsSentinel Lymph Node Biopsy

Identifiers

PMID40064798
PMCPMC11976756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.